Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist

Overview

Learn about tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, the active ingredient in Zepbound® (tirzepatide) and Mounjaro® (tirzepatide). In this program, we will review clinical efficacy, safety, and dosing and administration information about Zepbound and Mounjaro. Attendees will have the opportunity to ask questions to the speaker at the conclusion of the program.

Please see the Important Safety Information for Zepbound, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.zepbound.lilly.com/hcp.

Please see the Important Safety Information for Mounjaro, including Boxed Warning, the full Prescribing Information, and Medication Guide provided at the product theater and available on www.mounjaro.lilly.com/hcp.

This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

Mounjaro® and Zepbound® and their delivery device bases are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.